Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is getting substantial support from taxpayers but says when complete, it will more than double its workforce there.
Having laid out plans last fall to expand a biologics plant in the U.S., AstraZeneca is now planning to build a new large-molecule filling facility in Sweden, adding up to 250 jobs in the process. The U.K. drugmaker says the new facility is part of a bigger plan for its biologics manufacturing, the details of which it will announce later.
India's Wockhardt may have two of its plants banned by the FDA from shipping to the U.S. but it still has product on the market and it says some of it needs to be recalled. The drugmaker is retrieving nearly 95,000 bottles of blood pressure tablets because they are out of spec for thickness.
POPULAR COMMENT THREADS
Illinois-based specialty generics maker Akorn is recalling more than 355,000 bottles of its generic of Bactrim made by one of its recent acquisitions, a company it blamed for some of its financial woes.
Earlier this week, Endo said it would lay out $8 billion for Par Pharmaceuticals to get its hands on that company's sterile injectables biz. Now another deal is brewing in India forClaris Lifesciences operations in that part of the market.
Canadian generics maker Apotex is recalling more than 35,000 bottles of generic Zyprexa, an antipsychotic, that were manufactured at a plant in Toronto that was recently nicked by the FDA for a number of issues.
A fund for victims of a fungal meningitis outbreak that sprung from contaminated drugs sold by the now-defunct New England Compounding Center has reached $200 million, twice what was initially expected.
Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.
In a virtuous cycle, Johnson & Johnson is kicking in some more funding for continous manufacturing research by Rutgers University, whose engineers are helping J&J's Janssen unit transition some products to the new technology at a plant in Puerto Rico.
From Our Sister Sites
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.